{"doi":null,"coreId":"10413","oai":"oai:eprints.gla.ac.uk:48913","identifiers":["oai:eprints.gla.ac.uk:48913",null],"title":"A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies","authors":["Martin, N","Krol, P.","Smith, S.","Murray, K.","Pilkington, C.A.","Davidson, J.E.","Wedderburn, L.R.","Gardner-Medwin, J. [JD Research Group]","Juvenile Dermatomyositis Research Group"],"enrichments":{"references":[{"id":18090362,"title":"Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.","authors":[],"date":null,"doi":"10.1093\/rheumatology\/ken136","raw":"28 Marhaug G, Shah V, Shroff R et al. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology 2008;47: 1031\u20137. 29 Salomonsson S, Grundtman C, Zhang SJ et al. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle.","cites":null},{"id":668431,"title":"Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology 2008;47:","authors":[],"date":null,"doi":"10.1093\/rheumatology\/ken136","raw":null,"cites":null},{"id":668426,"title":"An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology","authors":[],"date":"2006","doi":"10.1093\/rheumatology\/kel025","raw":"23 Brown VE, Pilkington CA, Feldman BM, Davidson JE. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 2006; 45:990\u20133.","cites":null},{"id":18090349,"title":"Chung A et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children.","authors":[],"date":"1998","doi":null,"raw":"20 Pachman LM, Hayford JR, Chung A et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998;25:1198\u2013204.","cites":null},{"id":18090342,"title":"Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum","authors":[],"date":"2009","doi":"10.1002\/art.24571","raw":"13 Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge R, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009;60:1825\u201330.","cites":null},{"id":18090373,"title":"Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology","authors":[],"date":"2008","doi":"10.1093\/rheumatology\/ken074","raw":"39 Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 2008;47:877\u201380.","cites":null},{"id":668428,"title":"Failure to over express MHC-CLASS-1 on muscle biopsy in a case of amyopathic juvenile dermatomyositis. Clin Exp Rheumatol","authors":[],"date":"2007","doi":null,"raw":"25 McCann LJ, Li CK, Varsani H, Wedderburn LR, Pilkington CA. Failure to over express MHC-CLASS-1 on muscle biopsy in a case of amyopathic juvenile dermatomyositis. Clin Exp Rheumatol 2007;25:96\u20138.","cites":null},{"id":18090337,"title":"HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology","authors":[],"date":"2007","doi":"10.1093\/rheumatology\/kem265","raw":"6 Wedderburn LR, McHugh NJ, Chinoy H et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 2007;46:1786\u201391.","cites":null},{"id":18090370,"title":"HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PMScl antibody positive idiopathic inflammatory myopathy. Rheumatology","authors":[],"date":"2009","doi":"10.1093\/rheumatology\/kep248","raw":"36 Chinoy H, Payne D, Poulton K et al. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PMScl antibody positive idiopathic inflammatory myopathy. Rheumatology 2009;48:1213\u20137.","cites":null},{"id":668429,"title":"Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum","authors":[],"date":"2008","doi":"10.1002\/art.23202","raw":"26 Elst EF, Klein M, de Jager W et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 2008;58:547\u201355.","cites":null},{"id":18090347,"title":"International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials.","authors":[],"date":null,"doi":"10.1002\/art.23012","raw":"18 Wedderburn LR, Varsani H, Li CK et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007;57: 1192\u2013201.","cites":null},{"id":18090374,"title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology","authors":[],"date":"2004","doi":"10.1093\/rheumatology\/keg427","raw":"40 Isenberg DA, Allen E, Farewell V et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004; 43:49\u201354. 41 Rider LG, Giannini EH, Harris-Love M et al. Defining clinical improvement in adult and juvenile myositis.","cites":null},{"id":18090372,"title":"Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology","authors":[],"date":"2004","doi":"10.1093\/rheumatology\/keh082","raw":"38 Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology 2004;43:491\u20136.","cites":null},{"id":18090332,"title":"Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.","authors":[],"date":null,"doi":"10.1016\/j.berh.2009.07.007","raw":"1 Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 2009;23: 665\u201378.","cites":null},{"id":18090339,"title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients.","authors":[],"date":null,"doi":"10.1002\/acr.20015","raw":"Autoimmun Rev 2007;6:241\u20137. 10 Ravelli A, Trail L, Ferrari C et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients.","cites":null},{"id":18090350,"title":"Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541\u20139. 22 Pachman","authors":[],"date":null,"doi":"10.1002\/1529-0131(200003)43:3<541::aid-anr9>3.0.co;2-t","raw":"21 Huber AM, Lang B, LeBlanc CM et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541\u20139. 22 Pachman LM, Lipton R, Ramsey-Goldman R et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.","cites":null},{"id":668427,"title":"MHC Class I overexpression on muscles in early juvenile dermatomyositis.","authors":[],"date":null,"doi":null,"raw":"24 Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004;31: 605\u20139.","cites":null},{"id":673746,"title":"National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary\u2014clinical characteristics and disease course of","authors":[],"date":null,"doi":"10.1080\/08916930600622819","raw":null,"cites":null},{"id":18090376,"title":"National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary\u2014clinical characteristics and disease course of 44 patients with juvenile dermatomyositis.","authors":[],"date":null,"doi":"10.1080\/08916930600622819","raw":"43 Constantin T, Ponyi A, Orban I et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary\u2014clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 2006;39:223\u201332.","cites":null},{"id":18090371,"title":"Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology","authors":[],"date":"2007","doi":"10.1093\/rheumatology\/kem131","raw":"37 McCann LJ, Garay SM, Ryan MM, Harris R, Riley P, Pilkington CA. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 2007;46:1363\u20136.","cites":null},{"id":668433,"title":"Over expression of MHC class l heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis.","authors":[],"date":null,"doi":"10.2353\/ajpath.2009.090196","raw":"Muscle Nerve 2009;39:674\u201382. 30 Li C, Knopp P, Moncrieffe H et al. Over expression of MHC class l heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis.","cites":null},{"id":673747,"title":"patients with juvenile dermatomyositis.","authors":[],"date":null,"doi":"10.1007\/springerreference_38834","raw":null,"cites":null},{"id":18090341,"title":"Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum","authors":[],"date":"2008","doi":"10.1002\/art.23299","raw":"12 Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008;58:571\u20136.","cites":null},{"id":18090333,"title":"Polymyositis and dermatomyositis (first of two parts).","authors":[],"date":"1975","doi":null,"raw":"2 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344\u20137.","cites":null},{"id":18090335,"title":"Polymyositis and dermatomyositis (second of two parts).","authors":[],"date":"1975","doi":null,"raw":"3 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403\u20137.","cites":null},{"id":18090340,"title":"Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features.","authors":[],"date":null,"doi":"10.1002\/art.23960","raw":"11 Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008;58: 3585\u201392.","cites":null},{"id":673748,"title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.","authors":[],"date":"2011","doi":"10.1093\/rheumatology\/40.11.1262","raw":null,"cites":null},{"id":18090375,"title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference.","authors":[],"date":null,"doi":"10.1002\/acr.20071","raw":"J Rheumatol 2003;30:603\u201317. 42 Huber AM, Giannini EH, Bowyer SL et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference.","cites":null},{"id":673741,"title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res 2010;62:219\u201325.","authors":[],"date":null,"doi":"10.1002\/acr.20071","raw":null,"cites":null},{"id":668430,"title":"Quantification of normal range of inflammatory changes in morphologically normal pediatric muscle. Muscle Nerve","authors":[],"date":"2008","doi":"10.1002\/mus.20898","raw":"27 Varsani H, Newton KR, Li CK, Harding B, Holton JL, Wedderburn LR. Quantification of normal range of inflammatory changes in morphologically normal pediatric muscle. Muscle Nerve 2008;37:259\u201361.","cites":null},{"id":668434,"title":"Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis.","authors":[],"date":null,"doi":"10.1093\/rheumatology\/keh130","raw":"31 Maillard SM, Jones R, Owens C et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 2004;43:603\u20138.","cites":null},{"id":668435,"title":"Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis.","authors":[],"date":null,"doi":"10.1002\/art.21332","raw":"32 Maillard SM, Jones R, Owens CM et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 2005;53:558\u201364. 33 Gunawardena H, Wedderburn LR, Chinoy H et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.","cites":null},{"id":18090338,"title":"Rheumatol 2009;21:575\u201380. 9 Rider LG. The heterogeneity of juvenile myositis.","authors":[],"date":null,"doi":null,"raw":"Curr Opin Rheumatol 2009;21:575\u201380. 9 Rider LG. The heterogeneity of juvenile myositis.","cites":null},{"id":18090336,"title":"The incidence of juvenile dermatomyositis: results from a nation-wide study.","authors":[],"date":"1995","doi":"10.1093\/rheumatology\/34.8.732","raw":"4 Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995;34:732\u20136.","cites":null},{"id":18090348,"title":"The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)\u2014clinical characteristics of children recruited within the first 5 yr.","authors":[],"date":null,"doi":"10.1093\/rheumatology\/kel099","raw":"19 McCann LJ, Juggins AD, Maillard SM et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)\u2014clinical characteristics of children recruited within the first 5 yr. Rheumatology 2006;45: 1255\u201360.","cites":null},{"id":668432,"title":"Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle.","authors":[],"date":null,"doi":"10.1002\/mus.21129","raw":null,"cites":null},{"id":18090345,"title":"Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50:1595\u2013603.","authors":[],"date":null,"doi":"10.1002\/art.20179","raw":"16 Huber AM, Feldman BM, Rennebohm RM et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50:1595\u2013603.","cites":null},{"id":18090346,"title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 2010;62:465\u201372.","authors":[],"date":null,"doi":"10.1002\/acr.20035","raw":"17 Rider LG, Koziol D, Giannini EH et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 2010;62:465\u201372.","cites":null},{"id":18090344,"title":"Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.","authors":[],"date":null,"doi":"10.1002\/art.20179","raw":"15 Huber AM, Hicks JE, Lachenbruch PA et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001;28:1106\u201311.","cites":null}],"documentType":{"type":1}},"contributors":[],"datePublished":"2011-01","abstract":"Objectives: The paediatric idiopathic inflammatory myopathies (IIMs) are a group of rare chronic inflammatory disorders of childhood, affecting muscle, skin and other organs. There is a severe lack of evidence base for current treatment protocols in juvenile myositis. The rarity of these conditions means that multicentre collaboration is vital to facilitate studies of pathogenesis, treatment and disease outcomes. We have established a national registry and repository for childhood IIM, which aims to improve knowledge, facilitate research and clinical trials, and ultimately to improve outcomes for these patients. \\ud\nMethods: A UK-wide network of centres and research group was established to contribute to the study. Standardized patient assessment, data collection forms and sample protocols were agreed. The Biobank includes collection of peripheral blood mononuclear cells, serum, genomic DNA and biopsy material. An independent steering committee was established to oversee the use of data\/samples. Centre training was provided for patient assessment, data collection and entry. \\ud\nResults: Ten years after inception, the study has recruited 285 children, of which 258 have JDM or juvenile PM; 86% of the cases have contributed the biological samples. Serial sampling linked directly to the clinical database makes this a highly valuable resource. The study has been a platform for 20 sub-studies and attracted considerable funding support. Assessment of children with myositis in contributing centres has changed through participation in this study. \\ud\nConclusions: This establishment of a multicentre registry and Biobank has facilitated research and contributed to progress in the management of a complex group of rare muscloskeletal conditions","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Oxford University Press","rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.gla.ac.uk:48913<\/identifier><datestamp>\n      2016-08-25T11:33:02Z<\/datestamp><setSpec>\n      7374617475733D707562<\/setSpec><setSpec>\n      7375626A656374733D52:524A<\/setSpec><setSpec>\n      74797065733D61727469636C65<\/setSpec><\/header><metadata><rioxx xmlns=\"http:\/\/www.rioxx.net\/schema\/v2.0\/rioxx\/\" xmlns:ali=\"http:\/\/ali.niso.org\/2014\/ali\/1.0\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:dcterms=\"http:\/\/purl.org\/dc\/terms\/\" xmlns:rioxxterms=\"http:\/\/docs.rioxx.net\/schema\/v2.0\/rioxxterms\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.rioxx.net\/schema\/v2.0\/rioxx\/ http:\/\/www.rioxx.net\/schema\/v2.0\/rioxx\/rioxx.xsd\" ><ali:free_to_read>\n    \n      <\/ali:free_to_read><ali:license_ref start_date=\"2011-01\" >http:\/\/creativecommons.org\/licenses\/by-nc\/3.0<\/ali:license_ref><dc:description>Objectives: The paediatric idiopathic inflammatory myopathies (IIMs) are a group of rare chronic inflammatory disorders of childhood, affecting muscle, skin and other organs. There is a severe lack of evidence base for current treatment protocols in juvenile myositis. The rarity of these conditions means that multicentre collaboration is vital to facilitate studies of pathogenesis, treatment and disease outcomes. We have established a national registry and repository for childhood IIM, which aims to improve knowledge, facilitate research and clinical trials, and ultimately to improve outcomes for these patients. \\ud\nMethods: A UK-wide network of centres and research group was established to contribute to the study. Standardized patient assessment, data collection forms and sample protocols were agreed. The Biobank includes collection of peripheral blood mononuclear cells, serum, genomic DNA and biopsy material. An independent steering committee was established to oversee the use of data\/samples. Centre training was provided for patient assessment, data collection and entry. \\ud\nResults: Ten years after inception, the study has recruited 285 children, of which 258 have JDM or juvenile PM; 86% of the cases have contributed the biological samples. Serial sampling linked directly to the clinical database makes this a highly valuable resource. The study has been a platform for 20 sub-studies and attracted considerable funding support. Assessment of children with myositis in contributing centres has changed through participation in this study. \\ud\nConclusions: This establishment of a multicentre registry and Biobank has facilitated research and contributed to progress in the management of a complex group of rare muscloskeletal conditions.<\/dc:description><dc:format>application\/pdf<\/dc:format><dc:identifier>http:\/\/eprints.gla.ac.uk\/48913\/1\/48913.pdf<\/dc:identifier><dc:language>en<\/dc:language><dc:publisher>Oxford University Press<\/dc:publisher><dc:source>1462-0324<\/dc:source><dc:subject>RJ<\/dc:subject><dc:title>A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies<\/dc:title><rioxxterms:author>Martin, N<\/rioxxterms:author><rioxxterms:author>Krol, P.<\/rioxxterms:author><rioxxterms:author>Smith, S.<\/rioxxterms:author><rioxxterms:author>Murray, K.<\/rioxxterms:author><rioxxterms:author>Pilkington, C.A.<\/rioxxterms:author><rioxxterms:author>Davidson, J.E.<\/rioxxterms:author><rioxxterms:author>Wedderburn, L.R.<\/rioxxterms:author><rioxxterms:author>Gardner-Medwin, J. [JD Research Group]<\/rioxxterms:author><rioxxterms:author>Juvenile Dermatomyositis Research Group<\/rioxxterms:author><rioxxterms:publication_date>2011-01<\/rioxxterms:publication_date><rioxxterms:type>Journal Article\/Review<\/rioxxterms:type><rioxxterms:version>NA<\/rioxxterms:version><rioxxterms:version_of_record>http:\/\/dx.doi.org\/10.1093\/rheumatology\/keq261<\/rioxxterms:version_of_record><\/rioxx><\/metadata><\/record>","journals":null,"language":{"code":"en","id":9,"name":"English"},"relations":[],"year":2011,"topics":["RJ"],"subject":["RJ"],"fullText":""}